Loading...
24 diet COVID-19 controlled studies
48% improvement, RR
0.52
[0.44-0.62]
https://c19early.org/dtmeta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Mahto
20%
0.80 [0.49-1.21]
IgG+
23/206
70/483
Improvement, RR [CI]
Treatment
Control
Naushin
40%
0.60 [0.50-0.71]
seropositive
n/a
n/a
Kim
72%
0.28 [0.10-0.82]
m/s case
41 (n)
527 (n)
Kim
59%
0.41 [0.16-0.99]
m/s case
46 (n)
522 (n)
Kim
19%
0.81 [0.56-1.15]
cases
41 (n)
527 (n)
Kim
23%
0.77 [0.55-1.08]
cases
46 (n)
522 (n)
Merino
41%
0.59 [0.47-0.74]
severe case
148,142 (n)
148,143 (n)
Merino
18%
0.82 [0.78-0.86]
cases
148,142 (n)
148,143 (n)
Merino
9%
0.91 [0.88-0.94]
cases
148,142 (n)
148,143 (n)
Moludi
92%
0.08 [0.05-0.19]
cases
n/a
n/a
Ahmadi
-3%
1.03 [0.77-1.39]
death
185/206,286
62/75,264
Nguyen
15%
0.85 [0.75-0.96]
symp. case
345/1,054
433/1,082
Yamamoto
66%
0.34 [0.13-0.85]
cases
4/20
19/32
Magaña
53%
0.47 [0.22-0.99]
death
58 (n)
31 (n)
Jagielski
82%
0.18 [0.04-0.65]
cases
4/40
9/20
Perez-Araluce
78%
0.22 [0.03-1.77]
severe case
1/1,103
10/3,300
Perez-Araluce
15%
0.85 [0.62-1.15]
symp. case
52/1,103
214/3,300
Perez-Araluce
20%
0.80 [0.60-1.07]
cases
58/1,103
248/3,300
Firoozi
65%
0.35 [0.28-0.43]
cases
case control
per unit E-DII change
Hou
72%
0.28 [0.04-1.95]
severe case
1/22
78/487
Hou
11%
0.89 [0.58-1.36]
m/s case
11/22
273/487
Hou
74%
0.26 [0.10-0.67]
severe case
0/9
47/127
Hou
35%
0.65 [0.43-0.99]
m/s case
5/9
108/127
Zargarzadeh
77%
0.23 [0.11-0.50]
severe case
89 (n)
80 (n)
Yue
19%
0.81 [0.69-0.94]
cases
n/a
n/a
Yue
21%
0.79 [0.67-0.94]
cases
n/a
n/a
Yue
29%
0.71 [0.61-0.83]
cases
n/a
n/a
Yue
12%
0.88 [0.76-1.02]
cases
n/a
n/a
Zhou
16%
0.84 [0.78-0.91]
cases
1,321/10,254
1,935/10,253
Ebrahimzadeh
69%
0.31 [0.14-0.68]
severe case
n/a
n/a
Ebrahimzadeh
56%
0.44 [0.18-1.06]
hosp.
n/a
n/a
Ebrahimzadeh
68%
0.32 [0.15-0.68]
no recov.
n/a
n/a
Tadbir Vajargah
67%
0.33 [0.16-0.69]
severe case
83 (n)
83 (n)
Tadbir Vajargah
72%
0.28 [0.14-0.58]
severe case
83 (n)
83 (n)
Tadbir Vajargah
75%
0.25 [0.12-0.53]
severe case
83 (n)
83 (n)
Reis
75%
0.25 [0.12-0.52]
hosp.
17/380
21/166
Zhao
24%
0.76 [0.53-1.09]
death
39,230 (n)
39,231 (n)
Zhao
30%
0.70 [0.50-0.99]
death
39,230 (n)
39,231 (n)
Zhao
28%
0.72 [0.60-0.86]
severe case
39,230 (n)
39,231 (n)
Zhao
29%
0.71 [0.60-0.85]
severe case
39,230 (n)
39,231 (n)
Zhao
15%
0.85 [0.81-0.91]
cases
39,230 (n)
39,231 (n)
Zhao
9%
0.91 [0.85-0.96]
cases
39,230 (n)
39,231 (n)
Mohajeri
25%
0.75 [0.63-0.88]
progression
62/105
392/495
Mohajeri
51%
0.49 [0.40-0.60]
progression
50/105
482/495
Mohajeri
70%
0.30 [0.21-0.43]
progression
23/105
365/495
Mohajeri
-10%
1.10 [1.03-1.17]
progression
98/105
421/495
Mohajeri
53%
0.47 [0.36-0.61]
progression
38/105
380/495
Mohajeri
26%
0.74 [0.58-0.94]
progression
44/105
280/495
Wang
9%
0.91 [0.72-1.14]
PASC
124/318
218/480
LONG COVID
Wang
49%
0.51 [0.33-0.78]
PASC
188 (n)
66 (n)
LONG COVID
Zamanian
81%
0.19 [0.07-0.55]
hosp.
case control
Barania Adabi
99%
0.01 [0.00-0.21]
ICU
0/125
37/125
Barania Adabi
98%
0.02 [0.00-0.31]
ICU
0/125
26/125
Diet COVID-19 outcomes
c19 early.org/dt May 2023
Favors healthy diet
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit